2019

Theraclion Demonstrates Its Leadership in Thyroid and Veins None Invasive Treatments - Seite 2

 

126

 

+52%

Total Sales Theraclion SA

 

2,784

 

1,928

 

+44%

 

 

 

 

 

 

 

Incl Sales Echopulse

 

2,111

 

1,928

 

+10%

Incl Sales SONOVEIN

 

673

 

0

 

na

In line with the overall strategy, system sales fuel growth while Theraclion is enrolling key opinion leaders on SONOVEIN solution with a pay-per-use business model in direct markets and sales to distributors in other markets.

Thus, system sales, which account for 85% of the business in 2019, were up 45% compared to 2018. Eleven Echopulse and SONOVEIN systems were sold in 2019 (six in Germany, one in Spain, four in Asia and in the Middle East), compared to seven in 2018. In Germany, Theraclion benefits from the broadening of the reimbursement of echotherapy for the treatment of thyroid nodules and breast fibroadenoma. Outside Europe, Theraclion sold SONOVEIN solution to distributors who provide it to reference doctors specialized in veins who already use SONOVEIN to operate. Those sales confirm the international appetite of doctors for Theraclion’s disruptive solutions.

Recurring revenue, consisting of the sale of consumables and services, increased by 41% in 2019, from € 306,000 to € 433,000.

Four veins centers using SONOVEIN in 2019

Following CE marking of the SONOVEIN in April 2019, the first commercial treatments started in May. Four veins centers in Europe (UK, Germany, Czech Republic and Austria) currently use SONOVEIN echotherapy to treat varicose veins. Theraclion works hand in hand with these first KOLs to train the medical community. The SONOVEIN solution should, after a ramp-up period, generate a very significant recurrent revenue per site, a source of high and recurring free cash flow.